Accelerated LVAD pump thrombosis in COVID-19 patient: Case report and mini review

Article Infectious Diseases

Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study

Edward Burn et al.

Summary: The incidence of venous thromboembolism and arterial thromboembolism among COVID-19 cases is up to 1% and increases with hospitalization. These events are associated with excess mortality.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Surgery

Arterial Thrombosis in Coronavirus Disease 2019 Patients: A Rapid Systematic Review

Isaac Cheruiyot et al.

Summary: The study revealed that about 4% of critically ill COVID-19 patients experience arterial thrombotic events, with most patients being male, elderly, and having comorbidities. Arterial thrombosis is often symptomatic and can affect multiple arteries. The mortality rate in these patients is approximately 20%. Further investigation into the underlying mechanisms of arterial thrombosis in COVID-19 is needed to identify potential therapeutic targets.

ANNALS OF VASCULAR SURGERY (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Rapidly Progressive Left Ventricular Assist Device Outflow Graft Thrombosis Associated With COVID-19 Infection

Valmiki Maharaj et al.

CIRCULATION-HEART FAILURE (2021)

Add to Collection

Article Engineering, Biomedical

Identification of characteristics, risk factors, and predictors of recurrent LVAD thrombosis: conditions in HeartWare devices

Takayuki Gyoten et al.

Summary: Recurrent HVAD thrombosis mostly occurs within 12 months after the initial event. Systemic t-PA therapy for recurrent pump thrombosis appears to be safe and achieves comparable effectiveness rates to initial t-PA therapy. Survival rates do not differ significantly between patients with or without recurrent HVAD thrombosis.

JOURNAL OF ARTIFICIAL ORGANS (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Arterial Thrombosis and Coronavirus Disease 2019

Robert D. McBane

MAYO CLINIC PROCEEDINGS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Pump thrombosis and dynamic outflow graft compression: complications in left ventricular assist device therapy

Stephan Dobner et al.

Summary: Over the past decade, left ventricular assist device (VAD) therapy has become more prevalent and safer, but severe complications such as VAD pump thrombosis and outflow graft obstruction still carry a high morbidity and mortality rate. Early intervention is crucial in preventing adverse cardiac remodeling or VAD pump failure.

ESC HEART FAILURE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support

Edo Y. Birati et al.

Summary: This study describes the clinical characteristics and outcomes of COVID-19 in patients with end-stage heart failure and durable LVADs. The most common presenting symptoms were cough, fever, and fatigue, with 18% of patients being asymptomatic at diagnosis. Over half of the patients required hospitalization, with a high mortality rate of 20%. Understanding these characteristics is crucial in improving the outcomes of this complex patient population.

CIRCULATION-HEART FAILURE (2021)

Add to Collection

Article

Left Ventricular Assist Device Pump Thrombosis in a Patient Treated with Apixaban

Mansour A. Alkhunaizi et al.

American Journal of Case Reports (2021)

Add to Collection

Article Engineering, Biomedical

Impact of COVID-19 on Patients Supported with a Left Ventricular Assist Device

Jack Zakrzewski et al.

Summary: LVAD patients with COVID-19 are at increased risk of morbidity and mortality, with admission to the ICU and the need for mechanical ventilation being associated with mortality. Patients who previously had COVID-19 and underwent LVAD implantation experienced a complicated postoperative course, with a higher incidence of ischemic stroke and mortality.

ASAIO JOURNAL (2021)

Add to Collection

Article Biophysics

Physical phenotype of blood cells is altered in COVID-19

Marketa Kubankova et al.

Summary: Various physical parameters of blood cells, including lymphocyte stiffness, monocyte size, neutrophil size and deformability, and heterogeneity of erythrocyte deformation and size, were found to change significantly in COVID-19 patients. While some of these changes recovered after hospitalization, others persisted for months after discharge, demonstrating the long-term impact of COVID-19 on the body.

BIOPHYSICAL JOURNAL (2021)

Add to Collection

Review Hematology